article thumbnail

Daxxify, a New Anti-Wrinkle Drug and Botox Competitor is FDA-Approved

XTalks

Daxxify was FDA-approved for similar cosmetic purposes as Botox and other neuromodulators like Dysport and Xeomin. One of the first options made available for such purposes was Botox from Allergan, brought to health practitioners’ offices in 1989. A Novel Botox Competitor.

Botox 98
article thumbnail

Skin Tone Explored: Unraveling Complexities Through Research!

Trialfacts

More Study Details About the Research Center: Location Research Center: Validated Claim Support Location: Teaneck, New Jersey Lead Researcher: Anna Hardy About the Study Are you curious about your skin’s unique characteristics? Participate in this exclusive skin research study and discover the secrets of your skin tone!

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

U.S. FDA Accepts AbbVie’s New Drug Application for Atogepant for the Preventive Treatment of Migraine

The Pharma Data

2] – The atogepant application demonstrates AbbVie’s longstanding commitment to providing multiple migraine treatment options, including BOTOX® (onabotulinumtoxinA), a preventive treatment for those with chronic migraine, and UBRELVY® (ubrogepant), an acute treatment for adults with migraine. IMPORTANT SAFETY INFORMATION.

Botox 52
article thumbnail

AbbVie to Highlight Its Leadership in Movement Disorders at the.

The Pharma Data

“Our research presented at MDS 2021 builds upon our expertise in neuroscience and reinforces our mission to advance the standards of care for people living with these debilitating diseases.” BOTOX ® Abstracts. BOTOX ® (onabotulinumtoxinA) Important Information.

Botox 52
article thumbnail

Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting

The Pharma Data

Researchers will present data from several studies on migraine, including new findings on atogepant, AbbVie’s investigational preventive treatment of migraine in adults who meet criteria for episodic migraine as well as results evaluating the efficacy and safety of BOTOX ® (onabotulinumtoxinA) and UBRELVY ® (ubrogepant).

Botox 52
article thumbnail

GW Pharma Hopes to Bring Its Second Cannabis-Based Drug to Market in the U.S.

The Pharma Data

Food and Drug Administration, Gover said he believes there is a “clear path” to the submission of a New Drug Application as soon as 2021. as research shows a significant percentage of spasticity patients are today self-medicating using unapproved cannabis products to relieve their spasticity,” Gover said in a statement.

article thumbnail

AbbVie adds to neuroscience pipeline with $1bn Syndesi buy

pharmaphorum

The total value of the deal could rise to $1 billion, dependent on whether Syndesi’s SV2A drugs – headed by early-stage clinical candidate SDI-118 – progress in development and reach the market.

Botox 52